Click Here to
Subscribe
Breaking
News, Updates,
& More
Stay Up
to Date

The HARMONY Alliance: Novel Insights into Genomic Classification and Prognosis in Acute Myeloid Leukemia

2020 Year in Review - AML - Leukemia

Analyses of large cohorts of data are needed to understand how genetic aberrations can affect treatment outcomes in patients with hematologic malignancies (HMs). With this in mind, the HARMONY Alliance has developed a large platform for HMs called “Big Data for Better Outcome,” and aims to analyze approximately 100,000 cases of acute myeloid leukemia (AML), acute lymphocytic leukemia, chronic lymphocytic leukemia, multiple myeloma, myelodysplastic syndromes, non-Hodgkin lymphoma, and pediatric HMs. This report focused on results from the first approximately 5000 AML cases and served as proof of principle.

The Observational Medical Outcomes Partnership (OMOP) common data model was used to implement de facto anonymization and data harmonization. Thereafter, the following analyses were performed: gene–gene interaction analyses for co-occurrence and mutual exclusivity, a hierarchical Dirichlet process for class discovery, and a Bradley-Terry analysis to estimate clonal evolution. Prognostic multistage models were fitted to assess the effects of genomic and clinical data on rates of remission, relapse, and survival.

Data from 2941 patients with AML with available clinical and molecular information were analyzed. The median age was 52.4 years, and 53% of patients were male. A total of 808, 1193, and 940 patients had favorable, intermediate, and adverse cytogenetics, respectively, according to the European LeukemiaNet (ELN) 2017 risk classification. A total of 1251 patients received an allogeneic stem-cell transplantation (allo-SCT); 1690 patients received conventional consolidation.

Analysis of gene–gene interactions confirmed known patterns of co-occurrence and mutual exclusivity. Furthermore, cluster analysis enabled segmentation of “unique” ELN risk groups. Overall, these data were able to establish that epigenetic driver mutations in genes affecting DNA methylation occur very early, whereas histone-modifying enzyme mutations occur later. Finally, these data confirm that the presence of high-risk mutations differentially influences overall survival (OS) following an allo-SCT in a complex manner. Indeed, patients whose disease exhibits many high-risk genotypes, such as the TP53 mutation, seem to derive modest benefit from an allo-SCT (median OS of 54.4 weeks and 12.8 weeks with vs without allo-SCT, respectively; P <.001). However, patients whose disease exhibits other higher-risk genotypes, such as DNMT3A in combination with PTPN11, benefit more significantly from an allo-SCT (median OS of 212.7 weeks and 60.8 weeks with vs without allo-SCT, respectively; P = .027).

Results from this proof-of-principle study combining large data cohorts of clinical outcomes and disease genomic profiling from patients with AML confirm the benefit of similar approaches using the HARMONY Alliance platform, and demonstrate that analyses of OMOP-harmonized big data sets will help inform individualized therapy for optimal outcomes in other HMs.

Reference
Bullinger L, Martinez Elicegui J, Strang E, et al. Novel Insights into Genomic Classification and Prognosis in Acute Myeloid Leukemia Based on a Pan-European Public-Private Partnership, the HARMONY Alliance. Presented at: 25th European Hematology Association Congress Virtual; June 11-21, 2020. Abstract S130.

Related Items
Retrospective Study of Single Cord Blood Transplantation for Patients with AML Aged ≥60 Years
2020 Year in Review - AML published on December 17, 2020 in Leukemia
Enasidenib Monotherapy with Addition of Azacitidine in Nonresponders Effective in Older Patients with Newly Diagnosed, IDH2-Mutated AML
2020 Year in Review - AML published on December 17, 2020 in Leukemia
Characteristics and Prognostic Effects of IDH Mutations Across the Age Spectrum in AML: A Collaborative Analysis
2020 Year in Review - AML published on December 17, 2020 in Leukemia
Effect of Early Blood Counts on Response and Overall SurvEffect of Early Blood Counts on Response and Overall Survival Following Glasdegib + LDAC in Newly Diagnosed AMLival Following Glasdegib + LDAC in Newly Diagnosed AML
2020 Year in Review - AML published on December 17, 2020 in Leukemia
Venetoclax plus Standard Intensive AML Induction/Consolidation with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML
2020 Year in Review - AML published on December 17, 2020 in Leukemia
Clinical Outcomes for Treatment-Naïve Patients with AML Ineligible for Intensive Chemotherapy Receiving Azacitidine or Decitabine
2020 Year in Review - AML published on December 17, 2020 in Leukemia
SAL-DaunoDouble Trial Interim Analysis: Single versus Double Induction with 7+3 for Patients with Newly Diagnosed AML
2020 Year in Review - AML published on December 17, 2020 in Leukemia
Prognostic Significance of Concomitant Gene Mutations in Intensively Treated Patients with IDH1/2 Mutated AML
2020 Year in Review - AML published on December 17, 2020 in Leukemia
Decitabine + Venetoclax versus Intensive Chemotherapy for Patients with Relapsed/Refractory AML: A Propensity Score–Matched Analysis
2020 Year in Review - AML published on December 17, 2020 in Leukemia
Escalated Dosing Schedules of CC-486 Effective for Patients Experiencing First AML Low Blast Count Relapse
2020 Year in Review - AML published on December 15, 2020 in Leukemia
Last modified: December 17, 2020